. Author manuscript; available in PMC: 2011 Feb 1.

Published in final edited form as: Cancer. 2010 Feb 1;116(3):749–757. doi: 10.1002/cncr.24844

Table 1.

Anti-angiogenic strategies evaluated in preclinical studies of Ewing sarcoma.

Strategy	Specific Example	Preclinical Model	Ref

Reducing VEGF Expression	si-RNA against VEGF	TC71 xenograft	32

Binding VEGF	Bevacizumab	RD-ES and A673 xenografts	34
Binding VEGF	VEGF Trap	RD-ES, A673, and SK-NEP xenografts	33, 34

Inhibiting VEGF Receptor(s)	Anti-VEGFR-2 monoclonal antibody	TC71 xenograft	14
	Cedirinib (AZD2171)	PPTP panel	35
	Sunitinib (SU11248)	PPTP panel	36
	SU5416	RD-ES and A673 xenografts	34
	SU6668	RD-ES and A673 xenografts	34

Augmenting Endogenous	Increasing thrombospondin expression	TC71 and TC667 xenografts	19
Anti-Angiogenic Pathways	Increasing VEGF_165b expression	TC71 xenograft	37

si-RNA = small interfering RNA; PPTP panel = panel of Ewing sarcoma cell lines and xenografts used by the Pediatric Preclinical Testing program